Edition:
United States

Tasly Pharmaceutical Group Co Ltd (600535.SS)

600535.SS on Shanghai Stock Exchange

40.46CNY
11:29pm EDT
Change (% chg)

¥-0.07 (-0.17%)
Prev Close
¥40.53
Open
¥40.86
Day's High
¥40.86
Day's Low
¥40.11
Volume
1,292,017
Avg. Vol
4,140,512
52-wk High
¥45.28
52-wk Low
¥34.10

Latest Key Developments (Source: Significant Developments)

China's Tasly Pharma, France's Pharnext plan JV in China
Tuesday, 9 May 2017 07:36am EDT 

May 9 (Reuters) - Tasly Pharmaceutical Group Co Ltd <600535.SS>:Says unit plans to invest 20 million euros ($21.79 million) in Pharnext S.A. For 12.6 percent stake.Says it and Pharnext plan to invest 200 million yuan to set up JV in China for technology innovation and product development.  Full Article

Tasly Pharmaceutical's Q1 net profit up 14.8 pct y/y
Friday, 14 Apr 2017 04:27am EDT 

Tasly Pharmaceutical Group Co Ltd <600535.SS> :Says Q1 net profit up 14.8 percent y/y at 318.1 million yuan ($46.19 million).  Full Article

Tasly Pharmaceutical to pay annual cash div as 5.60 yuan per 10 shares for FY 2016
Sunday, 2 Apr 2017 11:47am EDT 

Tasly Pharmaceutical Group Co Ltd <600535.SS> :Says it plans to pay annual cash dividend as 5.60 yuan(pre-tax) per 10 shares as FY 2016 div payment.  Full Article

Tasly Pharmaceutical's 2016 profit down, to issue up to 2 bln yuan commercial paper
Thursday, 30 Mar 2017 08:30am EDT 

Tasly Pharmaceutical Group Co Ltd <600535.SS> : Says 2016 net profit down 20.4 percent y/y .Says it plans to issue up to 2.0 billion yuan ($290.36 million) commercial paper.  Full Article

Tasly Pharmaceutical group's sub-subsidiary to invest in Shanghai bio-tech firm after merged by unit
Friday, 24 Mar 2017 07:36am EDT 

Tasly Pharmaceutical Group Co Ltd <600535.SS> : Says Tianjin-based firm Genexine, in which co's unit owns 33.34 percent stake, signed cooperation framework agreement to merge a Shanghai-based bio-tech firm . Says the Shanghai-based bio-tech firm will be wholly owned by Tianjin-based firm Genexine .Says co's bio-tech sub-subsidiary and CBC Investment I-Mab Limited will boost capital of $38.3 million and $111.8 million to the merged entity respectively.  Full Article

Tasly Pharmaceutical Group says positive result from Topline Analysis Report of compound Danshen dripping pills
Monday, 26 Dec 2016 05:42am EST 

Tasly Pharmaceutical Group <600535.SS>: Says the Topline Analysis Report of its compound Danshen dripping pills proves that its compound Danshen dripping pills have positive treatment effect for angina pectoris .Says the clinic trial is for the New Drug Application of U.S FDA.  Full Article

Tasly Pharmaceutical Group issues debentures worth 1 bln yuan
Wednesday, 16 Nov 2016 04:53am EST 

Tasly Pharmaceutical Group Co Ltd <600535.SS>:Says it issued 2016 third tranche super short-term debentures worth 1 billion yuan with a term of 270 days and interest rate of 3.16 percent.  Full Article

Tasly Pharmaceutical Group unit gets nod for clinic trial
Monday, 15 Aug 2016 01:02am EDT 

Tasly Pharmaceutical Group Co Ltd <600535.SS>:Says its unit gets China Food and Drug Administration's approval for an injection's clinic trial.  Full Article

Tasly Pharma's H1 net profit down 17.5 pct
Friday, 12 Aug 2016 07:00am EDT 

Tasly Pharmaceutical Group Co Ltd <600535.SS> :Says H1 net profit down 17.5 percent y/y at 684.8 million yuan ($103.06 million).  Full Article

Tasly Pharmaceutical Group to pay 2015 dividend on May 25
Wednesday, 18 May 2016 02:30am EDT 

Tasly Pharmaceutical Group Co., Ltd. <600535.SS> : Says it will pay cash dividend of 0.42 yuan per share (before tax) for 2015 to shareholders of A shares of record on May 24 .Says company's shares will be traded ex-right and ex-dividend on May 25 and the dividend will be paid on May 25.  Full Article

More From Around the Web

BRIEF-China's Tasly Pharma, France's Pharnext plan JV in China

* Says unit plans to invest 20 million euros ($21.79 million) in Pharnext S.A. For 12.6 percent stake